the impact of acalabrutinib treatment by line of therapy in patients with cll
Published 1 month ago • 107 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:19
long-term management of cll for improved outcomes
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
1:56
the future of fixed-duration therapy in cll
-
5:39
acalabrutinib monotherapy in mature b-cell malignancies
-
1:22
long-term outcomes and toxicities of ibrutinib in cll
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
51:19
interpretation of hplc report for hemoglobinopathies
-
5:06
evolution of btk inhibitors in cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
3:10
ascend: acalabrutinib in r/r cll
-
1:24
sequencing of btk inhibitors in cll
-
1:04
a phase i/ii study evaluating ms-553 in patients with cll/sll
-
5:20
advances in the use of bispecific antibodies for the treatment of cll
-
1:32
an update from bellwave-001: nemtabrutinib in cll/sll
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:19
cll treatment: a look into the future
-
0:51
phase i study of copanlisib plus venetoclax in r/r dlbcl
-
2:39
updates from the phase i/ii bruin study: pirtobrutinib in cll
-
3:13
selection for time-limited & continuous therapy in cll
-
2:37
allo-hsct for cll in the era of novel agents
-
1:11
telomere dysfunction to predict clinical outcomes in cll